Amyloidosis Therapeutics Market Gears Up for a New Era in Precision Medicine


The global amyloidosis therapeutics market is poised for substantial growth, with its value expected to surge from US$ 5.17 billion in 2025 to US$ 8.20 billion by 2032, registering a robust CAGR of 6.8% during the forecast period from 2025 to 2032. This expansion is being driven by a combination of rising disease prevalence, increased awareness, early detection through advanced diagnostics, and innovative therapeutic approaches, including the integration of artificial intelligence in diagnosis and treatment pathways.

Understanding Amyloidosis and Market Drivers

Amyloidosis is a complex and often underdiagnosed disease caused by the accumulation of amyloid proteins in various organs. The most common types include AL (primary), AA (secondary), hereditary (familial), wild-type (senile), and localized amyloidosis. These variants can impact vital organs such as the heart (cardiac amyloidosis), kidneys, liver, and nervous system. Risk factors include aging, chronic inflammatory diseases, genetic predisposition, and prolonged dialysis.

The disease poses significant clinical challenges due to its non-specific symptoms and potential for multi-organ damage. Left untreated, it can lead to heart failure, kidney dysfunction, and severe neurological complications. However, improved diagnostic technologies, heightened clinical awareness, and the emergence of personalized therapies are propelling market growth.

Market Dynamics

Drivers – Early Detection and Diagnostic Innovation

Early diagnosis of cardiac amyloidosis (CA) is critical as it dramatically affects patient outcomes. Advanced diagnostic tools, including echocardiography, cardiac MRI, and nuclear imaging, are essential in identifying the condition. Technologies like late gadolinium enhancement (LGE) and radiotracer-based imaging play a pivotal role in distinguishing between amyloid subtypes, allowing clinicians to tailor treatment strategies effectively.

AI-enabled diagnostic models have significantly boosted early detection rates. For instance, convolutional neural networks (CNNs) have demonstrated expert-level accuracy in identifying amyloidosis through imaging data, especially in identifying early-stage CA. AI-enhanced scintigraphy has shown superior prognostic capabilities by accurately stratifying patient risks.

Restraints – High Cost and Treatment Accessibility

One of the major hindrances to market expansion is the high cost of amyloidosis therapies. Disease-modifying agents for ATTR amyloidosis, such as tafamidis, patisiran, and vutrisiran, often range between US$ 200,000 and US$ 500,000 annually. Tafamidis, marketed as Vyndaqel/Vyndamax in the U.S., costs around US$ 225,000 per year, limiting its accessibility despite FDA approval. Likewise, gene-silencing therapies like inotersen are priced similarly, raising affordability concerns in public health systems.

A recent cost-effectiveness study indicated tafamidis would require over a 90% price reduction to align with standard U.S. value-based care thresholds, underscoring the economic burden faced by healthcare systems and patients alike.

Opportunities – AI-Powered Innovation in Diagnosis and Prognosis

Artificial intelligence represents a transformative opportunity for the amyloidosis therapeutics market. The use of CNN-based AI models in imaging analysis has demonstrated exceptional capabilities in predicting disease progression, identifying patients at high risk, and guiding timely interventions. A MedUni Vienna-led research initiative validated an AI system using scintigraphy data from over 16,000 patients across Europe and Asia, showing a twofold higher mortality risk and a 17-fold increase in heart failure risk among AI-flagged patients.

This innovation is crucial in addressing underdiagnosis, particularly in early-stage cardiac involvement, and is expected to significantly improve patient outcomes and expand treatment demand.

Treatment Insights

By treatment, the chemotherapy segment is anticipated to lead in 2025 with approximately 33% market share. AL amyloidosis, one of the most severe subtypes, results from misfolded immunoglobulin light chains forming amyloid fibrils in organs like the heart and kidneys. Chemotherapy, particularly high-dose melphalan combined with autologous stem cell transplant (ASCT), remains the cornerstone of treatment.

Newer therapies include proteasome inhibitors (e.g., bortezomib) and immunomodulatory agents like lenalidomide and pomalidomide. These drugs are increasingly used in combination regimens to suppress abnormal plasma cells producing amyloidogenic proteins. The approval of monoclonal antibodies such as daratumumab by the FDA has further expanded the therapeutic arsenal.

Immunosuppressive drugs are projected to witness the fastest growth through 2032, driven by their effectiveness in managing the underlying plasma cell dyscrasias. Drugs like dexamethasone, often used in combination with other agents, have become standard in many treatment protocols.

End-User Insights

Hospitals and clinics are expected to dominate the market by end-user in 2025, holding around 51% of the global share. The diagnostic and treatment complexity of amyloidosis, including the need for biopsies, MRI scans, and targeted drug regimens, necessitates specialist care environments. Institutions like Mayo Clinic and Vienna General Hospital offer comprehensive diagnostic and therapeutic programs involving cardiologists, hematologists, and nephrologists.

Meanwhile, the home care segment is experiencing rapid growth, particularly in North America and Europe. This trend is driven by the growing elderly population, advancements in telemedicine, and cost-efficiency of long-term home-based care. Remote patient monitoring and teleconsultation platforms support treatment adherence and enhance patient comfort.

Regional Insights

North America

North America is forecasted to retain its dominance in the global amyloidosis therapeutics market in 2025, with a projected 47% market share. This leadership is attributed to its robust healthcare infrastructure, rapid adoption of advanced diagnostics, and a surge in novel drug approvals.

The U.S. market has particularly benefited from FDA-approved treatments like tafamidis, patisiran, and more recently, Acoramidis (Attruby), priced at US$ 18,759 per 28-day supply, offering a cost-effective alternative. Institutions like the Amyloidosis Program of Calgary and Ultromics’ AI platform, EchoGo Amyloidosis, have further propelled early detection efforts and therapeutic personalization.

Europe

Europe is also witnessing significant momentum, led by countries in the EU4 (Germany, France, Italy, and the U.K.). Regulatory bodies such as the European Medicines Agency (EMA) have approved advanced therapeutics including vutrisiran (Amvuttra), tafamidis, and eplontersen.

The U.K.'s National Amyloidosis Centre monitors over 6,400 patients and integrates patient education with clinical care. Germany, projected to be the fastest-growing market in Europe, manages more than 10,500 amyloidosis patients through university hospitals and benefits from supportive reimbursement frameworks through its Federal Joint Committee (G-BA).

Asia Pacific

The Asia Pacific region is emerging as a key growth frontier, driven by improved healthcare access, early diagnostic interventions, and accelerated regulatory approvals. Countries like Japan and China are leading this progress through strategic government support and healthcare innovation.

Japan’s adoption of cardiac PYP scans and early RNA-based therapies has significantly improved ATTR-CM detection. China, through its National Rare Disease List and National Medical Products Administration (NMPA), is facilitating faster orphan drug approvals. The approval of Darzalex Faspro (daratumumab) for AL amyloidosis exemplifies this forward momentum.

Competitive Landscape

The competitive landscape is marked by a blend of pharmaceutical giants and emerging biotech innovators. Key players include Pfizer, Johnson & Johnson (Janssen), Takeda Pharmaceutical, Amgen, Novartis, and Alnylam Pharmaceuticals, all actively developing advanced therapies for AL and ATTR amyloidosis.

These companies are aggressively investing in clinical trials, R&D partnerships, and strategic acquisitions. For instance, Alnylam’s AMVUTTRA® received FDA approval in March 2025 for ATTR-CM, expanding the treatment options for a wider patient demographic. In February 2025, the European Commission approved Beyonttra™ (acoramidis) for ATTR-CM, reflecting the region's supportive regulatory stance.

Key Developments in 2025

  • In March 2025, Alnylam Pharmaceuticals secured FDA approval for AMVUTTRA® (vutrisiran) for ATTR-CM treatment in adults.

  • In February 2025, the European Commission granted marketing authorization for Beyonttra™ (acoramidis) for patients with wild-type or variant transthyretin amyloidosis.

Companies Covered in the Market

  • Pfizer Inc.

  • Johnson & Johnson Services, Inc.

  • GSK plc

  • Takeda Pharmaceutical Company Limited

  • Amgen Inc.

  • Bristol-Myers Squibb Company

  • Novartis AG

  • F. Hoffmann-La Roche Ltd.

  • Merck KGaA

  • Sanofi

  • Alnylam Pharmaceuticals, Inc.

Conclusion

The global amyloidosis therapeutics market is on a transformative trajectory, shaped by technological advancements, strategic collaborations, and increasing disease awareness. As stakeholders continue to address challenges like high therapy costs and diagnostic complexity, the integration of AI and the development of novel therapeutics promise to reshape the treatment paradigm and improve patient outcomes across the globe.

Read Related Reports:

Cooling Therapy Devices Market

Intraocular Lens Injectors Market

Dural Sealant Market

Biotechnological Enzymes Market

Comments

Post a Comment

Popular posts from this blog

Legionella Testing Market Expansion Supported by Rising Awareness of Legionnaires’ Disease

Image
  The global legionella testing market , which is currently valued at USD 322.4 million in 2026, is projected to grow substantially, reaching USD 547.8 million by 2033. This robust growth represents a compound annual growth rate (CAGR) of 7.9% from 2026 to 2033. Several factors, including the rising incidence of Legionnaires' disease and increasing government regulations around water safety management, are fueling this expansion. As the prevalence of waterborne diseases like Legionnaires' disease escalates globally, the demand for reliable and efficient testing methods continues to rise, creating significant opportunities within the market. Market Dynamics: Drivers and Challenges Driver: Rising Incidence of Legionnaires' Disease and Aging Infrastructure One of the primary drivers of the legionella testing market’s growth is the increasing number of Legionnaires' disease cases globally. According to the Centers for Disease Control and Prevention (CDC), in the United Sta...
Read more

Antibody Testing Market Expands Amid Rising Demand for Accurate COVID-19 Screening Solutions

 The global antibody testing market is set for substantial expansion over the next decade, driven by growing demand for accurate diagnostic tools, increasing prevalence of infectious and chronic diseases, and significant advancements in immunodiagnostic technologies. According to the latest industry analysis, the global antibody testing market size is expected to be valued at US$9.4 billion in 2025 and projected to reach US$16 billion by 2032 , growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2025 to 2032. Market Overview Antibody testing, also known as serology testing, plays a crucial role in detecting the presence of antibodies in the blood, indicating an immune response to infections, vaccines, or autoimmune disorders. Over the past few years, the market has witnessed accelerated growth due to the increased demand for diagnostic tests following the COVID-19 pandemic. The rise in awareness regarding preventive healthcare, increasing healt...
Read more

UAE Health Check-up Market Set for Robust Growth Driven by Preventive Healthcare Initiatives

Image
  The UAE health check-up market is on a strong growth trajectory, projected to reach US$ 113.8 million by 2032, up from US$ 77.0 million in 2025, reflecting a compound annual growth rate (CAGR) of around 5.0% during the forecast period. This growth reflects a notable transformation in the UAE’s healthcare landscape, where residents are increasingly shifting from reactive treatment approaches to proactive, preventive care. Regular health check-ups are now being recognized as essential components of personal well-being rather than optional services. The growing focus on lifestyle disease management, government-led health campaigns, mandatory screenings for residency and employment, and innovative diagnostic technologies are driving this trend, particularly in urban hubs like Abu Dhabi and Dubai. Key Industry Highlights General health check-ups are expected to hold a dominant share in 2025, driven by the adoption of wellness programs among corporates. Companies are increasingly inco...
Read more